Background and aims Prescription opioid overdose is a leading cause of injury-related morbidity and mortality in the
INTRODUCTION

Prescription opioid abuse and overdose
Opioid abuse, addiction and overdose have reached proportions never seen before in the United States, and the death toll continues to rise. In 2012, 2.1 million Americans were estimated to have dependence or abuse of prescription opioids and 4.9 million, or 1.9% of the US population, were estimated to be non-medical users of prescription opioids [1] . Adverse events from prescription opioids were related to 855 348 emergency department (ED) visits in 2011 the United States [2] . Opioids were involved in 28 647 overdose deaths in the United States in 2014, accounting for 61% of overdose deaths overall [3] . More than half of those opioid-related deaths were due to prescription opioids, although it is increasingly difficult to determine exactly what proportion, as fentanyl-related deaths are increasing and fentanyl may originate in pharmaceutical or non-pharmaceutical sources [4] .
Overdose risk factors
Research has identified patient characteristics and prescribing practices that increase the risk of prescription opioid-related overdose and death. Patients with psychiatric disorders and those using benzodiazepines or illicit drugs have higher risk for opioid-related overdose and death [5, 6] . Recent release from prison increases the risk of prescription and non-prescription opioid-related overdose death, presumably from a loss of tolerance [7] . Higher doses of prescription opioids are also associated with more overdose deaths [8, 9] . Similarly, long-acting opioids are associated with increased risk for non-fatal overdose [10] . Among long-term opioid users on Medicaid, pharmacy shopping and overlapping prescriptions are associated with an increased risk for overdose [11] . Additionally, for patients on opioid substitution therapy in England and Wales, methadone had a relative risk of overdose death of 6.23 when compared with buprenorphine [12] . Among injection drug users in British Columbia, prescription opioid abuse was associated independently with overdose [13] . Recently, Zedler et al. examined insurance claims to derive risk factors for overdose or opioid-induced respiratory depression [14] . They found that among various comorbidities examined, a history of a substance use disorder was associated closely with the development of opioid-induced respiratory depression, with an odds ratio (OR) of 12.7. Additionally, of the different prescription opioids examined, fentanyl was the most closely associated with respiratory depression, with an OR of 3.7 [14] .
Overdose risk reduction
In response to the aforementioned research, numerous pain societies have released guidelines to encourage safer opioid prescribing, recommending interventions such as careful screening of patients for high-risk characteristics or behaviors, use of prescription drug monitoring programs and urine drug testing to detect aberrant behavior, lower dosing and slower titration of opioids with careful monitoring and use of non-opioid pain relievers preferentially over opioids when possible [5] . However, more research is needed to describe risk factors for adverse outcomes in patients who present to the emergency setting with prescription opioid overdose.
Naloxone is an important tool for harm-reduction in the midst of a nation-wide opioid epidemic. Naloxone is not only used in medical settings, but is utilized increasingly both by prehospital providers and in the community. Respiratory depression is the primary indication for naloxone [15] [16] [17] . In the prehospital setting in New York City, previous research suggests that emergency medical services (EMS) give naloxone mainly when there is either respiratory depression or coma with miotic pupils, and less often when there is suspected drug-related central nervous system (CNS) depression without clear hallmarks of an opioid toxidrome [18] . Data also show that EMS in New York City give naloxone less than half of the time when it would be indicated to treat opioid-poisoned patients [18] .
The present study
The objective of this study was to identify clinical characteristics associated with in-hospital morbidity and mortality among patients who presented to the ED following a prescription opioid overdose. Specifically, this study aimed primarily to identify predictors for in-hospital severe respiratory depression (SRD). We hypothesized that behaviors such as opioid misuse and demographics such as age would increase the risk for SRD. We also hypothesized that some prescription opioids would have greater risk for respiratory depression than others, particularly highpotency opioids such as fentanyl and opioids thought to have higher abuse potential such as methadone and oxycodone. An additional exploratory aim of the study was to identify predictors for mortality in ED patients with prescription opioid overdose.
METHODS
Study design
This was a secondary data analysis of a subgroup of patients with prescription opioid overdose taken from a larger prospective cohort of acute drug overdose cases, which has been described previously in more detail [19] . Briefly, the parent study was a prospective observational cohort of patients that presented with acute drug overdose to two urban teritiary-care emergency departments, which used elements of the routine ED evaluation to develop a prognostic tool to identify patients at risk for adverse cardiovascular events. The original study included 1562 individual patients for analysis. The current study examines the subgroup from the parent study that overdosed on prescription opioids. The following sections ('Setting', 'Participants' and 'Measurements') describe both the characteristics of the parent study as well as the specifics of the current subgroup analysis when they are distinct from the parent study. 'Outcomes' and 'Data analysis' refer to the current subgroup analysis only.
Setting
This study was conducted between 2009 and 2013 at two urban, tertiary-care hospitals (Mount Sinai Hospital and Elmhurst Hospital Center, both in New York, NY) that had a combined annual ED visit volume of more than 150 000 patients at the time the study was conducted. Neither study location was a regional referral center for toxicology patients, but a medical toxicology consult service was available at both hospitals.
Participants
In the parent study, patients with suspected drug overdose were screened by trained research assistants for inclusion. Patients were included who met both of the following criteria: (1) acute presentation (within 24 hours of exposure) and (2) suspected overdose (i.e. illicit drug dose sufficient to cause symptoms or any prescription drug exposure greater than its therapeutic dose). Exclusion criteria were the following: alternative diagnosis (e.g. trauma or infection), chronic presentation (i.e. not meeting acute criteria above), non-drug overdose (e.g. plant), age younger than 18 years, anaphylaxis, patients with incomplete data (i.e. left against medical advice, transferred to an outside institution or otherwise left the hospital), patients with prior do-not-attempt-resuscitation orders (i.e. prior to hospital admission) and prisoners. The current subgroup analysis examined those patients who had overdosed on prescription opioid medications, and included any patients from the parent study where a prescription opioid medication was involved. Patients who used illicit opioids (e.g. heroin) but not prescription opioids were not included. Patients who overdosed on prescription opioids plus other classes of drugs were included and were classified as multi-drug exposures. At the time of the study fentanyl was not reported present in the heroin or illicit supply, so all reported fentanyl cases were included in the prescription opioid group. Testing blood or urine for fentanyl was not part of routine practice at the institutions; all fentanyl cases described in this study were based on self-report of people who were exposed to fentanyl patches.
Measurements
In the parent study, patients were identified by a trained research assistant who circulated the ED during business hours to find acute overdose cases, and by cases who were called in to the poison center. While poison control center data were used for screening and inclusion, all other data, including outcomes, were abstracted from hospital medical records. Data were collected from the charts by research assistants trained in medical abstraction and recorded using standardized data collection forms. Random sampling of 10 charts with 95% agreement was performed prior to initiation of mass data extraction. Data were abstracted to a de-identified electronic database with password protection. Patients were followed prospectively during their hospital stay through to hospital discharge with data that included electronic medical records, paper medical records and consultation records. Results (from electronic physician notes, laboratory records, radiology results and discharge summaries) were available prospectively to the study investigators.
These data included demographics (sex, age, race), exposure information such as timing of exposure, number of exposures, toxin identification (detail from history and physical interview, serum drug concentrations if available), toxicology screens [urine enzyme-linked immunosorbent assay (ELISA) panel and serum concentration, if any], initial vital signs and initial venous blood gas, including serum lactate concentration. Blood and urine toxicology screen results sent as routine part of clinical care (i.e. no confirmatory gas chromatographic method coupled with mass spectrometry) were recorded to confirm exposure.
Prior to the initiation of data collection in the parent study, intent was categorized into four mutually exclusive categories: suicide, misuse, therapeutic error and undetermined. Patients were categorized into classes of intent based on chart review by trained research assistants without knowledge of study hypotheses. 'Suicide' was determined if history revealed that the patient was taking the medication in an attempt to end their life. Suicidal intent was defined according to the initial impression of the treating physician and confirmed by psychiatry consultation, with disagreements settled by psychiatry consultation note. Intent was classified further as 'misuse' if the patient was taking someone else's medication, was taking their own medication beyond the prescribed doses or was taking the medication to get high. Finally, unintentional poisoning with the patient's own medication at the prescribed dose was categorized as 'therapeutic error'.
Outcomes
The primary outcome for the study was the incidence of SRD, defined by either naloxone administration (either prehospital or in-hospital) or endotracheal intubation (ETI) performed either prehospital or in-hospital. The secondary outcome was in-hospital mortality, which was used for exploratory analysis.
Data analysis
Associations between clinical factors and the primary outcome were calculated using univariate analysis. Additionally, a multivariable model incorporated the following variables: age, opioid misuse, multi-drug exposure and hospital site. We calculated 95% confidence intervals using the estimated standard error method. Normality testing of demographic data (e.g. age) was confirmed using the Shapiro-Wilk test; χ 2 tests of independence (with twotailed Fisher's exact test when appropriate) and t-tests were calculated for categorical and continuous variables, respectively, with 5% alpha (two-tailed). Software used for analysis was SPSS version 20.
FINDINGS
Demographics
Of 354 prescription opioid overdose patients who were screened 47 were excluded, leaving 307 patients for analysis. Mean age was 44.7 years, and 42% were female.
Complete demographic data are presented in Table 1 
Intent of overdose and SRD
Intent of overdose for the study patients is summarized in Table 2 . Opioid misuse was associated significantly with SRD in the multivariable model (OR = 2.07, 95% CI = 1.21-3.55). Results from multivariable model are summarized in Table 3 . Opioid misuse was also associated with methadone overdose in the univariate analysis (OR = 3.1, 1.9-5.1). Suicidality was associated with codeine in the univariate analysis (OR = 2.7, CI = 1.2-6.3). Suicidality was correlated inversely with SRD in the univariate analysis (OR = 0.4, CI = 0.2-0.7), as well as overdose of methadone (OR = 0.4, CI = 0.2-0.6).
Vital signs and SRD
Initial ED vital signs for patients are summarized in Table 4 . Mean temperature, pulse, blood pressure, respiratory rate and saturation were similar between those with and without SRD. However, when using standard vital sign cutpoints, the following were associated with SRD: bradypnea (≤ 12 breaths per minute, OR = 12.3, CI = 2.7-55. 
Multi-drug exposure and SRD
Most patients reported ingesting more than one substance (n = 279, 91%). Multi-drug exposures were not associated with SRD in either the univariate or multivariable analysis. Serum drug concentrations were positive for ethanol in 51 patients, salicylate in three patients and acetaminophen in 52 patients. Serum drug concentrations were not performed uniformly in all patients, so these do not represent all patients that were exposed to these substances among this subgroup. Urine toxicology screening was performed in 171 patients, and was positive for benzodiazepines in 85 patients, cocaine in 45 patients, methadone in 60 patients, barbiturates in eight patients, amphetamines in two patients, phencyclidine (PCP) in four patients and cannabis in 10 patients.
Laboratory data and SRD
In 233 (75%) patients, venous blood gas was sent as part of the initial ED workup, and results are summarized in Table 4 . The following mean parameters were associated with SRD: pH, PCO 2 and lactate. Using a cut-point of 3 mmol/L, lactate was associated significantly with SRD (OR = 2.1, CI = 1.0-4.4) and mortality (OR = 32.6, CI = 3.7-289). However, SRD was not associated with either PO 2 or calculated bicarbonate. 
Type of prescription opioid and SRD
Risk for SRD was highly dependent upon the type of prescription opioid (Table 5 ). Of the overdoses involving fentanyl, 83.3% experienced SRD. Only 3.6% of overdoses involving codeine experienced SRD. Buprenorphine (28.6% SRD) had similar clinical severity to oxycodone (32% SRD) and hydrocodone (29% SRD). The two most frequent opioids, methadone and oxycodone, experienced SRD commonly (50.9 and 32.3%, respectively).
In-hospital mortality
Six patients (2%) died in-hospital, involving the following opioids (some had more than one): oxycodone (four), methadone (two 2), hydromorphone (one 1), and fentanyl (one ). There were no prehospital cardiac arrests, and two of six did not receive naloxone. Clinical factors associated with mortality compared with no mortality were initial tachycardia (≥ 100 beats per minute, P < 0.001), hyperlactatemia (≥ 3 mmol/L, P < 0.05) and initial hypotension (≤ 90 mmHg, P < 0.01).
DISCUSSION
Main results and implications
The main results of this study are that prescription opioid overdoses from misuse resulted in worse clinical severity than those from other intentions, such as suicidality. In addition, we found that clinical severity was correlated with age and the specific opioid medication. Given the Some patients ingested more than one type of opioid, so cumulative total of patients described in this table is greater than the number of patients in the study.
scope of this problem, providers and policymakers should consider ways to reduce harm associated with prescription opioid misuse. The results of this study suggest that some opioid medications are much higher-risk than others, which may lead providers to consider changing their prescribing practices to utilize opioid medication with lower risk.
Specific prescription opioids
It is notable that some prescription opioids had a much higher relative risk for SRD. Fentanyl, for example, had a relative risk of 22.5 compared to the lowest-risk opioid, codeine. Buprenorphine had a higher risk than would have been expected for this medication, which in therapeutic dose produces minimal respiratory depression in adults. As would be expected from previous research, buprenorphine had a lower risk than methadone. Methadone and oxycodone had relative risks of 13.7 and 8.7, respectively, but were collectively responsible for most of the cases of respiratory depression given the higher prevalence of their use compared to the other opioid medications. The results from this study reflect Centers for Disease Control (CDC) data on opioid related-deaths, which show that oxycodone, hydrocodone, methadone and fentanyl are particularly problematic among the available prescription opioids [4, 20] .
Urine drug screening was not able to confirm opioid exposure in most patients. This was in part because urine drug screening was only performed in 171 of 307 (56%) patients in this study. Additionally, commonly used assays test for opiates (i.e. natural or non-synthetic opioids such as morphine and codeine), with limited crossreactivity to detect semisynthetic opioids (buprenorphine, hydrocodone, hydromorphone, oxycodone) or synthetic opioids (tramadol, tapentadol, fentanyl, methadone). Only 12 of 307 (4%) reported morphine exposure, and 27 of 307 (9%) reported codeine exposure, meaning that the vast majority of patients in this study reported exposure to opioids that would not reliably test positive on an opiate screen.
Fentanyl
This study suggests that the risk of fentanyl to cause SRD appears to be particularly high when compared to other opioid medications, due possibly to the route of administration, the high potency or both. Fentanyl is a high-potency opioid often delivered in a patch form, which may lend itself to tampering to deliver much higher doses than ingestion of pills which may, in part, explain the high risk for SRD with this product. In 2012 the Food and Drug Administration (FDA) released a warning to the public about the risks associated with transdermal fentanyl patches when altered or not properly disposed [21] . Additionally, chest wall rigidity resulting from fentanyl exposure has been hypothesized to be a factor in fentanyl-related deaths [22] . Fentanyl-related deaths have grown dramatically since the completion of data collection in this study, due to both pharmaceutical and non-pharmaceutical fentanyl [4] . As testing for fentanyl was not part of routine clinical practice at the hospitals where this study was conducted, the cases of fentanyl overdose described in this study are based on self-report of fentanyl patches, and are almost certain to represent pharmaceutical fentanyl rather than non-pharmaceutical fentanyl that is sometimes added surreptitiously to the illicit drug supply.
Methadone and buprenorphine
In this cohort of prescription opioid overdose patients, methadone had a much higher risk for SRD than did buprenorphine. This supports previous research suggesting that buprenorphine is safer than methadone [12] . Currently, more patients are prescribed methadone than buprenorphine for opioid substitution therapy, and there are regulatory limits that make it difficult for providers to increase the number of patients treated with buprenorphine. Given the growing literature on the safety of buprenorphine compared to methadone, we urge policymakers to make regulatory changes that facilitate starting opioid-dependent patients on buprenorphine rather than methadone.
Prehospital naloxone
This research also adds to the growing body of literature about prehospital naloxone to treat prescription opioid overdose. We found that 13.4% of our cohort received prehospital naloxone. Many individuals who overdose on prescription opioids are not fortunate enough to arrive to a hospital in time to prevent respiratory depression and subsequent arrest, and prehospital naloxone is life-saving in many cases [23] . Unfortunately, the prehospital availability of naloxone is variable. Basic life support first responders are not authorized to administer naloxone in some of the United States [24] , although the number of states with laws increasing access of naloxone to laypeople is growing [25] . Policymakers should increase access of naloxone out of hospital, and develop protocols to ensure that prehospital providers are administering naloxone when appropriate. Naloxone programs should also be targeted to high-risk populations, such as those who were recently released from prison, a time when risk for opioid overdose is extremely high [7] . Additionally, policymakers should expand the use of Good-Samaritan laws, which help to protect bystanders who call for help in case of a witnessed overdose, and are not on the books in a number of states [25] .
